About us Contacts Drug interactions: 390 212
Drug search by name

Posaconazole Oral Suspension and Quin-G

Determining the interaction of Posaconazole Oral Suspension and Quin-G and the possibility of their joint administration.

Check result:
Posaconazole Oral Suspension <> Quin-G
Relevance: 10.06.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using quiNIDine together with posaconazole is not recommended. Combining these medications may significantly increase the blood levels of quiNIDine. High blood levels of quiNIDine can cause irregular heart rhythm that may be serious and potentially life-threatening. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, ringing in the ears, hearing loss, vision problems, diarrhea, and/or heart palpitations during treatment with quiNIDine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

CONTRAINDICATED: Coadministration with azole antifungal agents may significantly increase the plasma concentrations of quinidine. The proposed mechanism is inhibition of quinidine metabolism via intestinal and hepatic CYP450 3A4. Additionally, itraconazole and ketoconazole are also potent P-glycoprotein inhibitors and may reduce the active renal efflux of quinidine. In nine healthy, nonsmoking volunteers, administration of a single 100 mg oral dose of quinidine sulfate on the last day of itraconazole treatment (200 mg once a day for 4 days) increased quinidine peak plasma concentration (Cmax) and systemic exposure (AUC) by an average of 1.6- and 2.4-fold, respectively, compared to administration with placebo. The elimination half-life of quinidine was prolonged 60% by itraconazole, and its renal clearance decreased by 50%. Another study in six healthy subjects reported an approximately 60% decrease each in total and renal clearance and a 35% increase in elimination half-life of a single 200 mg dose of quinidine sulfate when given with itraconazole (100 mg daily for 6 days). Likewise, plasma quinidine levels more than doubled within seven days after initiating ketoconazole 200 mg/day in an elderly man taking quinidine sulfate 300 mg four times a day, although there was no evidence of clinical toxicity in this case. The use of quinidine has been associated with prolongation of the QT interval, thus elevated plasma levels may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death. Some azole antifungal agents themselves have also rarely been associated with QT interval prolongation and/or torsade de pointes. Theoretically, additive proarrhythmic effects may occur when used with quinidine. A case of deafness has been associated with quinidine toxicity attributed to a suspected interaction with itraconazole.

MANAGEMENT: Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of quinidine, concomitant use with azole antifungal agents is considered contraindicated.

References
  • Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32
  • "Product Information. Nizoral (ketoconazole)." Janssen Pharmaceutica, Titusville, NJ. (1992):
  • Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38
  • Laakso M, Aberg A, Savola J, Pentikainen PJ, Pyorala K "Diseases and drugs causing prolongation of the QT interval." Am J Cardiol 59 (1987): 862-5
  • Raehl CL, Patel AK, LeRoy M "Drug-induced torsade de pointes." Clin Pharm 4 (1985): 675-90
  • "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.
  • Holford NH, Coates PE, Guentert TW, Riegelman S, Sheiner LB "The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships." Br J Clin Pharmacol 11 (1981): 187-95
  • "Product Information. Diflucan (fluconazole)." Roerig Division, New York, NY.
  • Stanek EJ, Simko RJ, DeNofrio D, Pavri BB "Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure." Pharmacotherapy 17 (1997): 622-5
  • "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.
  • "Product Information. Sporonox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.
  • Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • Cerner Multum, Inc. "Australian Product Information." O 0
  • Roden DM, Woosley RL, Primm RK "Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care." Am Heart J 111 (1986): 1088-93
  • "Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.
  • McNulty RM, Lazor JA, Sketch M "Transient increase in plasma quinidine concentrations during ketoconazole-quinidine therapy." Clin Pharm 8 (1989): 222-5
Posaconazole Oral Suspension

Generic Name: posaconazole

Brand name: Noxafil

Synonyms: Posaconazole (oral/injection), Posaconazole

Quin-G

Generic Name: quinidine

Brand name: Quin-G, Cardioquin, Quinora, Quinidex Extentabs, Quinaglute Dura-Tabs, Quin-Release

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction